Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

ISS suggest Enhabit shareholders elect three AREX Capital nominees to board



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>ISS suggest Enhabit shareholders elect three AREX Capital nominees to board</title></head><body>

By Svea Herbst-Bayliss

July 11 (Reuters) -Institutional Shareholder Services (ISS) on Thursday said Enhabit EHAB.N shareholders should elect three AREX Capital Management director candidates to the nine member board, arguing the company needs more expertise in home health, hospice and public company financial reporting.

The prominent proxy advisory firm, whose recommendations often guide shareholder votes on proposed mergers and who serves on a board, said AREX made a convincing case that new directors are needed. But the hedge fund did not persuade ISS that a majority of the two-year-old company's directors should be ousted, the report reviewed by Reuters said.

AREX is asking investors to replace seven directors to help reverse poor financial performance. It has also been pushing the home health and hospice provider to put itself up for sale.

Investors will vote on July 25 unless the two sides reach an agreement before the meeting date.

"The company's significant underperformance, both from a TSR (total shareholder return) and operational standpoint, indicate that a degree of change is needed at the board level," ISS wrote. Enhabit's stock price has tumbled nearly 60% since it was spun off of post-acute healthcare services provider Encompass Health EHC.N in July 2022.

ISS recommended votes for AREX candidates Gregory Sheff, who has home health operations experience, Anna-Gene O'Neal, who has hospice experience, and Mark Ohlendorf, who has public company chief financial officer experience.

AREX, which owns a 4.9% stake in Enhabit, is backing Enhabit CEO Barbara Jacobsmeyer and director Barry Schochet for reelection. Schochet joined the board last year when the company reached an agreement with investors Cruiser Capital and Harbour Point Capital Management in March 2023.

AREX told Enhabit last year that it wanted the company to commit to immediately start a strategic review before the end of 2023. Enhabit in May said it decided to continue as an independent, public company after having evaluated a range of strategic options.

A company representative was not immediately available for comment on the ISS recommendation and AREX declined to comment.




Reporting by Svea Herbst-Bayliss; Editing by Christian Schmollinger

</body></html>

Mga Kaugnay na Asset


Pinakabagong Balita

Progressive rises after Q2 profit surges


U.S. STOCKS UnitedHealth, EPAM, Datadog

B
M
T
D
U
U
P

IMF raises India's GDP forecast to 7% for 2024-25


China's Zijin Mining to take 9.9% stake in Canada's Montage Gold

K

Energy Transfer, Sunoco form joint venture of Permian crude businesses

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.